검색
Emergent BioSolutions Inc
EBS관심 목록에 추가
7.220USD
-0.050-0.69%
종가 07-31 16:00（ET）시세는 15분 지연됩니다
372.53M시가총액
손실P/E TTM
자세한 내용은 Emergent BioSolutions Inc 회사
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Emergent BioSolutions Inc 정보
종목 코드 EBS
회사 이름Emergent BioSolutions Inc
상장일Nov 15, 2006
CEOPapa (Joseph C)
직원 수900
유형Ordinary Share
회계 연도 종료Nov 15
주소300 Professional Dr
도시GAITHERSBURG
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호20879
전화12406313200
웹사이트https://emergentbiosolutions.com/
종목 코드 EBS
상장일Nov 15, 2006
CEOPapa (Joseph C)
Emergent BioSolutions Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
114.67K
+22.10%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
89.36K
+28.36%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
79.44K
+31.90%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
59.03K
+16.71%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
자주 묻는 질문
Emergent BioSolutions Inc의 상위 5대 주주는 누구인가요?
Emergent BioSolutions Inc의 상위 5대 주주는 다음과 같습니다: Mr. Joseph C. (Joe) Papa
Emergent BioSolutions Inc(EBS)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Emergent BioSolutions Inc의 주식을 보유한 기관은 총 412곳이며, 이들이 보유한 주식의 총 가치는 약 42.30M로 전체 발행 주식의 81.98%를 차지합니다. 이는 2025Q4 대비 -3370363.00 증가한 수치입니다.
Emergent BioSolutions Inc의 최대 수익원은 무엇인가요?
2026Q1 기준, Emergent BioSolutions Inc의 Commercial Product sales 부문이 가장 높은 매출을 기록했으며, 금액은 223.30M로 전체 매출의 30.06%를 차지했습니다.